Filing Flows › Amneal Pharmaceuticals (AMRX) › Q3 2026 › vs Q2 2026
Amneal Pharmaceuticals (AMRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Amneal Pharmaceuticals's revenue rose $66.5M (+8%) from $796M in Q2 2026 to $863M in Q3 2026. Gross margin 38.7% against 42.0% (-3.3 pts).
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 38.7% | 42.0% | -3.3 pts |
| Operating margin | 11.1% | 16.3% | -5.2 pts |
| Net margin | 1.4% | 8.7% | -7.3 pts |
| Free cash flow margin | 7.7% | -6.5% | +14.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $863M | $796M | $66.5M | +8% |
| Gross profit | $334M | $335M | −$390K | -0.1% |
| Cost of revenue | $529M | $462M | $66.9M | +14% |
| Operating profit | $95.4M | $130M | −$34.4M | -26% |
| Operating expenses | $239M | $205M | $34.0M | +17% |
| Pre-tax earnings | $15.1M | $71.0M | −$55.9M | -79% |
| Other expense, net | $80.4M | $58.8M | $21.6M | +37% |
| Research & development | $68.4M | $39.0M | $29.4M | +75% |
| SG&A | $140M | $149M | −$9.1M | -6% |
| Other operating costs | $30.7M | $17.0M | $13.7M | +80% |
| Net earnings | $12.3M | $69.6M | −$57.3M | -82% |
| Income tax | $2.8M | $1.4M | $1.4M | +100% |
| Share-based compensation | $10.5M | $10.4M | $123K | +1% |
| Working capital & other | $75.5M | −$101M | $177M | — |
| Operating cash flow | $98.3M | −$21.2M | $120M | — |
| Free cash flow (OCF − capex) | $66.5M | −$51.9M | $118M | — |
| Capital expenditures | $31.8M | $30.7M | $1.1M | +4% |
Questions
How much did Amneal Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Amneal Pharmaceuticals's revenue rose $66.5M (+8%) from $796M in Q2 2026 to $863M in Q3 2026. Gross margin 38.7% against 42.0% (-3.3 pts).